Turkmenistan Certificate Holder Rules: Resident and Non-Resident Marketing Authorization Holders

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Turkmenistan permits both residents and non-residents to act as the registration certificate holder (marketing authorization holder). This is one of the rarely open arrangements in this market; in many CIS and emerging markets the certificate holder must be a local legal entity.

Behind the openness, however, stand 3 costs:

  • A non-resident holder must appoint a local representative, through whom registration and subsequent affairs are handled;
  • The authorization of the local representative rests on a power of attorney, and the POA must pass through the consular legalization chain (article 15);
  • The allocation of post-market responsibilities must be set out in the authorization documents (article 42).

2. Legal basis

Legal instrumentReference or numberPublication dateProvisions
Law of Turkmenistan on the Supply of MedicinesNo. 319-VJanuary 12, 2016Eligibility of applicants (residents and non-residents)
Regulation on National Registration of Medicines and Medical DevicesNo public number (approved by the Ministry of Health)Current versionApplicant eligibility and local representation
Hague Convention Abolishing Legalization of 1961None (international convention)Member list, January 2025 editionTurkmenistan is not a member (consular legalization of the POA)

3. Expert insights

Insight 1: A non-resident may hold the certificate, and a local agent is mandatory; these are requirements at two different levels.

The former resolves the ownership of rights: a Chinese company can be the holder in its own name and need not place the certificate in the name of somebody else. The latter resolves the capacity to act: without a local presence, someone must act on the spot. The two can coexist without contradiction. Confusing them produces two opposite errors: some applicants assume that appointing an agent transfers ownership of the certificate, while others assume that owning the certificate removes the need for any local presence. Both assumptions are wrong, and contracts should be drafted so that ownership and agency are kept strictly separate.

Insight 2: The ability to hold the certificate directly is one of the most valuable institutional arrangements of this market.

In markets that require a local holder, companies face the risk of losing control of a certificate asset: if the agency relationship deteriorates, the certificate can be held hostage. Turkmenistan allows non-resident holding, which means the company can keep the certificate in its own hands while using the POA to define the boundaries of what the local representative may do. For portfolio planning, this materially changes the risk profile of the market: the certificate can be consolidated, audited, and financed like any other intangible asset of the manufacturer, rather than sitting on the balance sheet of a distributor.

Insight 3: The quality of the POA determines how stable this structure is.

Since non-resident holding rests on the combination of direct ownership plus a local representative acting on behalf, the POA is the only connector of the entire structure. It must clearly state 4 items:

  • the scope of authorization (submission, collection of the certificate, variations, renewal, vigilance);
  • the term of authorization and the conditions of termination;
  • the responsibility for safekeeping the original certificate and the dossier;
  • the manner in which post-market obligations are borne.

Insight 4: Local representation requirements differ between sources and must be confirmed case by case.

As article 14 has disclosed, some sources state that non-resident applicants must appoint a local representative, while other sources state that an authorized representative is not required. We present this divergence as it stands and recommend confirming the current position in writing through a local partner before submission. The confirmation should be obtained from, or countersigned by, the competent authority where possible, because the operational reality at the registration counter, rather than the published rule, is what determines whether a file is accepted on the day of submission.

Insight 5: The resident-holder pathway suits companies with a long-term market commitment.

If the company maintains an entity or a joint venture in Turkmenistan, holding the certificate as a resident can remove parts of the legalization chain. This must, however, be weighed together with investment and tax arrangements; it is not a purely regulatory question. Establishing a local entity brings accounting, staffing, and compliance costs of its own, and the savings in legalization fees and time will rarely justify the structure on their own. The resident pathway is best treated as a by-product of a broader market entry decision rather than as a regulatory optimization pursued in isolation.

4. Practical recommendations

  1. Prefer direct holding by the non-resident manufacturer so that the certificate asset remains in the hands of the manufacturer.
  2. Write the POA to cover all four items: scope of authorization, term and termination, dossier safekeeping, and post-market obligations.
  3. Run the POA through the full consular legalization chain and mind document validity periods.
  4. Confirm the current local representation position in writing before submission.
  5. Companies with a local entity may evaluate the resident-holder pathway, planned together with investment and tax considerations.

5. Verification checklist

  • □ It has been determined that the certificate holder is the manufacturer (non-resident).
  • □ The POA covers all four authorization items.
  • □ The POA has completed the consular legalization chain.
  • □ The local representation position has been confirmed in writing.
  • □ The resident-holder pathway has been evaluated together with investment and tax matters (if applicable).

Regulatory information verified as of October 30, 2026. The content cited in this document has been checked against the Law of Turkmenistan on the Supply of Medicines No. 319-V (January 12, 2016; both residents and non-residents may act as applicants) and the Regulation on National Registration of Medicines and Medical Devices approved by the Ministry of Health. Regarding whether a non-resident must appoint a local representative, sources differ (one states that non-residents must appoint a local representative, another states that an authorized representative is not required); this divergence is disclosed as it stands, and the current position must be confirmed in writing with the competent authority or a local partner before submission.

  • Local resources in Turkmenistan: GRZAN can coordinate licensed local import entities and authorized representative resources, covering national registration submissions, the consular legalization chain for documents, sample delivery, interface with mandatory TDS certification, and customs clearance support.
  • Service capabilities: classification assessment, registration pathway selection, national-format dossier writing, notarization and consular legalization, preparation of test and stability documentation, organization of GMP and ISO 13485 evidence, variations and renewal, vigilance and post-market maintenance.
  • Contact: info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail